Dr. Mitchell Ryan Lunn, MD

Dr. Lunn practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Lunn's NPI, 1467773598, was assigned on June 11, 2010. Dr. Lunn graduated from Stanford University School Of Medicine in 2010. Dr. Lunn holds California license A124674.

Dr. Lunn's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Lunn's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Lunn to 1 more hospital and 1 medical group, each named with a free account. Dr. Lunn's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lunn practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Lunn's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Lunn is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Lunn's licenses on file in 2 states: California and Massachusetts.

Dmand AI lists chronic kidney disease among the conditions Dr. Lunn treats.

CMS data shows 420 Medicare services from Dr. Lunn across 3 procedure codes in 2024, for 128 Medicare patients. Medicare paid $45,794 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 128 Medicare patients who saw Dr. Lunn in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 53% are also on Medicaid. Their average risk score is 6.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lunn's median patient age at 58, with 37% women.

In 2023, Dr. Lunn wrote 29 Medicare Part D claims. They cover 2 drugs, with $5,696 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Lunn for performance year 2024, reported as part of a group. Dr. Lunn accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 94 papers to Dr. Lunn, published from 2010 to 2025. 2022 was the busiest year, with 12. The most frequent topics are Sexual and Gender Minorities, Sexual Behavior and Transgender Persons. Dr. Lunn has published most often in Body Image. Dr. Lunn's most frequent co-authors are Juno Obedin-Maliver, MD, Kirsten Beatrice Bibbins-Domingo, MD and Matthew Mansh.

Dmand AI links Dr. Lunn to 1 clinical trial. Conditions studied include Cigarette Smoking and Tobacco Smoking.

CMS Open Payments shows 13 general payments to Dr. Lunn from 3 drug and device companies from 2018 to 2024. Consulting fees make up the largest share, 78% of the total. Otsuka Pharmaceutical Development & Commercialization, Inc. paid the most, $8,631.

Dmand AI lists 12 awards for Dr. Lunn, most recently Resident Travel Award in 2011.

Dr. Lunn graduated from Stanford University School Of Medicine in 2010.

Dr. Lunn is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.